Molecularly imprinted phosphate binders for therapeutic use

• US 20050276781A1
• Filed: 06/09/2005
• Published: 12/15/2005
• Est. Priority Date: 06/09/2004
• Status: Abandoned Application

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Batich, Christopher D., Ross, Edward Allan
• Application Number:
  US11/148,929
• Publication Number:
  US 20050276781A1
• Time in Patent Office: Days
• US Class Current: 424/78.80
• CPC Class Codes: A61K 31/74 Synthetic polymeric materials
• CPC Class Codes: B01J 20/268 Polymers created by use of a template, e.g. molecularly imprinted polymers

Abstract

Methods for synthesizing molecularly imprinted polymers (MIP) having an affinity for dietary phosphates, resulting polymers, pharmaceutical compositions and modes of administration are disclosed. The MIP compounds are useful for binding excess dietary phosphates in a patient in need thereof.

Claims

1. A molecularly imprinted polymer (MIP) compound comprising:

a) a polymer, electrostatically imprinted with a phosphate, comprising at least one monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both, at least one cross-linking agent for structurally supporting the at least one monomer, and a plurality of binding sites for binding to phosphate ions, phosphate containing molecules, or a combination of both, wherein the binding sites are accessible by pores;

or

b) a polymer, electrostatically imprinted with a phosphate, comprising at least one monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both, at least one cross-linking agent for structurally supporting the at least one monomer, and a plurality of binding sites for binding to phosphate ions, phosphate containing molecules, or a combination of both, wherein the binding sites are accessible by pores, and a physical spacer.

2. The MIP compound according to claim 1, wherein the at least one monomer is selected from the group consisting of allylamine, methylmethacrylate;

hydroxyethylmethacrylate;

N,N-di-ethylamino ethyl methacrylate;

acrylic acid;

alkyl methacrylate;

alkylacrylate;

arylacrylate;

acrylamide;

methacrylamide;

N-methylacrylamide;

N-methylmethacrylamide;

styrene;

para-hydroxy-styrene;

para-amino-styrene;

vinylpyridine;

para-vinyl benzoic acid;

2-vinyl-2-hydroxypyridine;

3-vinyl-2-hydroxypyridine;

4-vinyl-2-hydroxypyridine;

4-vinylbenzamide;

N-alkyl-(4-vinylbenzamide);

N,N-dialkyl-(4-vinylbenzamide);

N,N′

-diethyl(4-vinylphenyl)amidine;

acrylonitriles;

ethacrylamide;

alkacrylamides;

alkyl substituted alkyl acrylates;

butadiene;

caprolactone;

ethylene;

propylene;

divinylbenzene;

ethylene glycol;

propylene glycol;

dimethylsiloxane;

lactide;

glycolide;

ornithine;

vinyl acetate;

vinyl alcohol;

vinyl chloride;

vinyl isobutyl ether;

vinyl methyl ether;

urethane;

isocyanates;

isothiocyanates;

dimethyl aminoethyl acrylate methyl chloride;

[2-(methacryloyloxy)ethyl]trimethylammonium chloride;

vinylpyrrolidone; and

combinations of any of the foregoing.

3. The MIP compound according to claim 1, wherein the at least one cross-linking agent is selected from the group consisting of difunctional acrylate;

trifunctional acrylate;

tetrafunctional acrylate;

difunctional methacrylate;

trifuncitonal methacrylate;

tetrafunctional methacrylate;

divinyl benzene;

alkylene glycol;

polyalkylene glycol diacrylate;

methacrylate;

dialkyldiglycol dicarbonate;

dialkyl maleate;

dialkyl fumurate;

dialkyl itaconate;

vinyl ester;

ethylene glycol dimethacrylate;

ethylene glycol diacrylate;

di-ethylene glycol diacrylate;

triethylene glycol diacrylate;

tetraethylene glycol diacrylate;

vinyl acrylate;

vinyl methacrylate;

alkyl acrylate;

divinylbenzene;

diallyldiglycol dicarbonate;

diallyl maleate;

diallyl fumarate;

diallyl itaconate;

vinyl ester;

divinyl oxalate;

divinyl malonate;

diallyl succinate;

triallyl isocyanurate;

dimethacrylate of bisphenol A;

diacrylate of bisphenol A;

dimethacrylate of ethoxylated bisphenol A;

diacrylate of ethoxylated bispherol A;

methylene;

polymethylene bisacrylamide;

bismethacrylamide;

hexamethylene bisacrylamide;

hexamethylene bismethacrylamide;

di(alkene)tertiary amine;

trimethylol propane triacrylate;

pentaerythritol tetraacrylate;

divinyl ether;

divinyl sulfone;

diallyl phthalate;

triallyl melamine;

2-isocyanatoethyl methacrylate;

2-isocyanatoethylacrylate;

3-isocyanatopropylacrylate;

1-methyl-2-isocyanatoethyl methacrylate;

1,1-dimethyl-2-isocyanaotoethyl acrylate;

tetraethylene glycol diacrylate;

tetraethylene glycol dimethacrylate;

triethylene glycol dimethacrylate;

hexanediol dimethacrylate;

hexanediol diacrylate; and

a combination of any of the foregoing.

4. The MIP compound according to claim 1, comprising about 3 wt % to about 35 wt % of the at least one cross-linker.

5. The MIP compound according to claim 1, wherein the physical spacer comprises polyethylene oxide, polyvinyl alcohol, bentonite clay, or a combination of the foregoing.

6. The MIP compound according to claim 1, wherein the compound is formulated as a particulate or a hydrogel.

7. A method for treating a patient having an excess of phosphate ions and/or phosphate containing molecules in the gastrointestinal tract, the method comprising:

a) administering an effective amount of a molecularly imprinted polymer (MIP) compound according to claim 1 to the gastrointestinal tract of the patient;

b) administering an effective amount of a MIP compound according to claim 1 to the gastrointestinal tract of the patient and monitoring serum phosphate levels in the patient;

c) administering an effective amount of a MIP compound according to claim 1 to the gastrointestinal tract of the patient, monitoring serum phosphate levels in the patient, and co-administering, sequentially or simultaneously, at least one pharmacologically active agent;

or

d) administering an effective amount of a MIP compound according to claim 1 to the gastrointestinal tract of the patient and co-administering, sequentially or simultaneously, at least one pharmacologically active agent;

wherein the at least one monomer of the MIP compound is selected from the group consisting of;

i) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both;

ii) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of allylamine;

methylmethacrylate;

hydroxyethylmethacrylate;

N,N-di-ethylamino ethyl methacrylate;

acrylic acid;

alkyl methacrylate;

alkylacrylate;

arylacrylate;

acrylamide;

methacrylamide;

N-methylacrylamide;

N-methylmethacrylamide;

styrene;

para-hydroxy-styrene;

para-amino-styrene;

vinylpyridine;

para-vinyl benzoic acid;

2-vinyl-2-hydroxypyridine;

3-vinyl-2-hydroxypyridine;

4-vinyl-2-hydroxypyridine;

4-vinylbenzamide;

N-alkyl-(4-vinylbenzamide);

N,N-dialkyl-(4-vinylbenzamide);

N,N′

-diethyl(4-vinylphenyl)amidine;

acrylonitrile;

ethacrylamide;

alkacrylamide;

alkyl substituted alkyl acrylate;

butadiene;

caprolactone;

ethylene;

propylene;

divinylbenzene;

ethylene glycol;

propylene glycol;

dimethylsiloxane;

lactide;

glycolide;

ornithine;

vinyl acetate;

vinyl alcohol;

vinyl chloride;

vinyl isobutyl ether;

vinyl methyl ether;

urethane;

isocyanates;

isothiocyanates;

dimethyl aminoethyl acrylate methyl chloride;

[2-(methacryloyloxy)ethyl]trimethylammonium chloride;

vinylpyrrolidone; and

combinations of any of the foregoing;

iii) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of hydroxyethyl methacrylate, methyl methacrylate, [2-(methacryloyloxy)ethyl]trimethylammonium chloride, acrylic acid, allylamine, and combinations of any of the foregoing; and

iv) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of styrene, parahydroxy-styrene, para-amino styrene, vinyl-pyridine, para-vinyl benzoic acid, and combinations of the foregoing;

wherein the at least one cross-linking agent of the MIP compound is selected from the group consisting of;

v) difunctional acrylate;

trifunctional acrylate;

tetrafunctional acrylate;

difunctional methacrylate;

trifunctional methacrylate;

tetrafunctional methacrylate;

divinyl benzene;

alkylene glycol;

polyalkylene glycol diacrylate;

methacrylate;

dialkyldiglycol dicarbonate;

dialkyl maleate;

dialkyl fumurate;

dialkyl itaconate;

vinyl ester;

ethylene glycol dimethacrylate;

ethylene glycol diacrylate;

diethylene glycol diacrylate;

triethylene glycol diacrylate;

tetraethylene glycol diacrylate;

vinyl acrylate;

vinyl methacrylate;

alkyl acrylate;

divinylbenzene;

diallyldiglycol dicarbonate;

diallyl maleate;

diallyl fumarate;

diallyl itaconate;

vinyl ester;

divinyl oxalate;

divinyl malonate;

diallyl succinate;

triallyl isocyanurate;

dimethacrylate of bisphenol A;

diacrylate of bisphenol A;

dimethacrylate of ethoxylated bisphenol A;

diacrylate of ethoxylated bispherol A;

methylene;

polymethylene bisacrylamide;

bismethacrylamide;

hexamethylene bisacrylamide;

hexamethylene bismethacrylamide;

di(alkene)tertiary amine;

trimethylol propane triacrylate;

pentaerythritol tetraacrylate;

divinyl ether;

divinyl sulfone;

diallyl phthalate;

triallyl melamine;

2-isocyanatoethyl methacrylate;

2-isocyanatoethylacrylate;

3-isocyanatopropylacrylate;

1-methyl-2-isocyanatoethyl methacrylate;

1,1-dimethyl-2-isocyanaotoethyl acrylate;

tetraethylene glycol diacrylate;

tetraethylene glycol dimethacrylate;

triethylene glycol dimethacrylate;

hexanediol dimethacrylate;

hexanediol diacrylate;

or a combination of any of the foregoing; and

vi) di-ethylene glycol diacrylate; and

wherein the physical spacer of the MIP compound is selected from the group consisting of;

vii) an inert particle; and

viii) an inert particle selected from the group consisting of polyethylene oxide, polyvinyl alcohol, bentonite clay, and a combination of any of the foregoing.

8. The method according to claim 7, wherein each of the administering steps comprise the patient ingesting the molecularly imprinted polymers.

9. The method according to claim 7, wherein the pharmacologically active agent is a phosphate sequestrant.

10. The method according to claim 7, wherein the MIP compound comprises two polar monomers, wherein the degree of polarity varies to the extent that the less polar monomer is relatively inactive when compared to the more polar monomer.

11. The method according to claim 7, wherein the weight percentage of cross-linking agent in the molecularly imprinted polymer is within the range of about 3 wt % to about 35 wt %.

12. The method according to claim 7, comprising administering the MIP compound as a hydrogel, a particulate, or a particulate formulated as a capsule or tablet.

13. A method for synthesizing a molecularly imprinted polymer (MIP) compound 1 having a complementary structure to phosphate ions, wherein the method comprises:

a) providing a mixture comprising;

at least one monomer;

at least one diluent; and

at least one cross-linking agent;

b) contacting a target imprint molecule with the provided mixture so that the at least one monomer self-assembles around the target imprint molecule in a lowest energy state for the at least one monomer;

c) polymerizing the at least one monomer, wherein the polymerized monomers are supported by the at least one cross-linking agent, wherein the polymerized monomers are electrostatically imprinted to the target imprint molecule, and

d) removing the target imprint molecule and the at least one diluent from the polymerized monomers, whereby a MIP compound according to claim 1 is formed;

or

e) providing a mixture comprising;

at least one monomer;

at least one pore forming diluent; and

at least one cross-linking agent;

f) contacting a target imprint molecule with the provided mixture so that the at least one monomer self-assembles around the target imprint molecule in a lowest energy state for the at least one monomer;

g) polymerizing the at least one monomer, wherein the polymerized monomers are supported by the at least one cross-linking agent, wherein the polymerized monomers are electrostatically imprinted to the target imprint molecule;

h) removing the target imprint molecule and the at least one diluent from the polymerized polymers, whereby a MIP compound according to claim 1 is formed; and

i) incorporating a physical spacer throughout the MIP compound or the polymerized monomers;

wherein the at least one monomer is selected from the group consisting of;

i) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both;

ii) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of allylamine;

methylmethacrylate;

hydroxyethylmethacrylate;

N,N-di-ethylamino ethyl methacrylate;

acrylic acid;

alkyl methacrylate;

alkylacrylate;

arylacrylate;

acrylamide;

methacrylamide;

N-methylacrylamide;

N-methylmethacrylamide;

styrene;

para-hydroxy-styrene;

para-amino-styrene;

vinylpyridine;

para-vinyl benzoic acid;

2-vinyl-2-hydroxypyridine;

3-vinyl-2-hydroxypyridine;

4-vinyl-2-hydroxypyridine;

4-vinylbenzamide;

N-alkyl-(4-vinylbenzamide);

N,N-dialkyl-(4-vinylbenzamide);

N,N′

-diethyl(4-vinylphenyl)amidine;

acrylonitrile;

ethacrylamide;

alkacrylamide;

alkyl substituted alkyl acrylate;

butadiene;

caprolactone;

ethylene;

propylene;

divinylbenzene;

ethylene glycol;

propylene glycol;

dimethylsiloxane;

lactide;

glycolide;

ornithine;

vinyl acetate;

vinyl alcohol;

vinyl chloride;

vinyl isobutyl ether;

vinyl methyl ether;

urethane;

isocyanates;

isothiocyanates;

dimethyl aminoethyl acrylate methyl chloride;

[2-(methacryloyloxy)ethyl]trimethylammonium chloride;

vinylpyrrolidone; and

combinations of any of the foregoing;

iii) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of hydroxyethyl methacrylate, methyl methacrylate, [2-(methacryloyloxy)ethyl]trimethylammonium chloride, acrylic acid, allylamine and combinations of any of the foregoing; and

iv) a monomer exhibiting an affinity for phosphate ions, phosphate containing molecules, or a combination of both selected from the group consisting of styrene, parahydroxy-styrene, para-amino styrene, vinyl-pyridine, para-vinyl benzoic acid, and combinations of the foregoing;

wherein the at least one cross-linking agent is selected from the group consisting of;

v) difunctional acrylate;

trifunctional acrylate;

tetrafunctional acrylate;

difunctional methacrylate;

trifunctional methacrylate;

tetrafunctional methacrylate;

divinyl benzene;

alkylene glycol;

polyalkylene glycol diacrylate;

methacrylate;

dialkyldiglycol dicarbonate;

dialkyl maleate;

dialkyl fumurate;

dialkyl itaconate;

vinyl ester;

ethylene glycol dimethacrylate;

ethylene glycol diacrylate;

diethylene glycol diacrylate;

triethylene glycol diacrylate;

tetraethylene glycol diacrylate;

vinyl acrylate;

vinyl methacrylate;

alkyl acrylate;

divinylbenzene;

diallyldiglycol dicarbonate;

diallyl maleate;

diallyl fumarate;

diallyl itaconate;

vinyl ester;

divinyl oxalate;

divinyl malonate;

diallyl succinate;

triallyl isocyanurate;

dimethacrylate of bisphenol A;

diacrylate of bisphenol A;

dimethacrylate of ethoxylated bisphenol A;

diacrylate of ethoxylated bispherol A;

methylene;

polymethylene bisacrylamide;

bismethacrylamide;

hexamethylene bisacrylamide;

hexamethylene bismethacrylamide;

di(alkene)tertiary amine;

trimethylol propane triacrylate;

pentaerythritol tetraacrylate;

divinyl ether;

divinyl sulfone;

diallyl phthalate;

triallyl melamine;

2-isocyanatoethyl methacrylate;

2-isocyanatoethylacrylate;

3-isocyanatopropylacrylate;

1-methyl-2-isocyanatoethyl methacrylate;

1,1-dimethyl-2-isocyanaotoethyl acrylate;

tetraethylene glycol diacrylate;

tetraethylene glycol dimethacrylate;

triethylene glycol dimethacrylate;

hexanediol dimethacrylate;

hexanediol diacrylate;

or a combination of any of the foregoing; and

vi) di-ethylene glycol diacrylate;

wherein the physical spacer is selected from the group consisting of;

vii) an inert particle; and

viii) an inert particle selected from the group consisting of polyethylene oxide, polyvinyl alcohol, bentonite clay, and a combination of any of the foregoing; and

wherein the at least one diluent comprises one diluent comprising isopropanol;

the at least one diluent comprises one diluent comprising hexane;

or the at least one dilent comprises two or more diluents selected from the group consisting of methanol, ethanol, t-butanol, octanol, isopropanol, hexane, and combinations of any of the foregoing.

14. The method according to claim 13, wherein the provided mixture comprises about 3 parts by volume of the at least one monomer per about 9 parts by volume of the at least one cross-linking agent.

15. The method according to claim 13, wherein the provided mixture comprises one part by weight of the at least one diluent per one part by weight of the at least one monomer.

16. The method according to claim 13, wherein the at least one monomer comprises a first polar monomer and a second polar monomer, and wherein the polarity of the first monomer is relatively inactive compared to the polarity of the second polar monomer.

17. The method according to claim 16, wherein the first polar monomer is selected from the group consisting of hydroxyethyl methacrylate, methyl methacrylate, and a combination of both;

and wherein the second polar monomer is selected from the group consisting of [2-(methacryloyloxy)ethyl]trimethyl ammonium, allylamine, and a combination of both.

18. The method according to claim 16, wherein the at least one monomer comprises about one part by weight of the first polar monomer and about two parts by weight of the second polar monomer.

19. The method according to claim 13, wherein the provided mixture comprises one part by weight of the at least one diluent and one part by weight of the at least one monomer.

20. The method according to claim 13, wherein the provided mixture comprises two diluents;

and wherein the provided mixture further comprises one part by weight of each of the two diluents and one part by weight of the at least one monomer.

21. The method according to claim 13, comprising the MIP compound comprising about 3 wt % to about 35 wt % of the at least one cross-linking agent.

22. The method according to claim 13, wherein the contacting step takes place at a temperature within the range of about 17°

C. to about 77°

C.

23. The method according to claim 13, wherein the polymerizing step is initiated using an initiator selected from the group consisting of benzol peroxide;

acetyl peroxide;

lauryl peroxide;

azobisisobutyronitrile;

2,2′

-Azobis(2-methylpropionamidine)dihydrochloride;

t-butyl peracetate;

cumyl peroxide;

t-butyl peroxide;

t-butyl hydroperoxide;

bis(isopropyl)peroxy-dicarbonate;

benzoin methyl ether;

2,2′

-azobis(2,4-dimethylvaleronitrile);

tert-butyl peroctoate;

phtalic peroxide;

diethoxyacetophenon;

tert-butyl peroxyypivalate;

diethoxyacetophenone;

1-hydroxycyclohexyl phenyl ketone;

2,2-dimethoxy-2-phenyl-acetophenone;

phenothiazine;

diisopropylxanthogen disulfide; and

a combination of any of the foregoing.

24. The method according to claim 13, wherein the removing step comprises:

a) a plurality of washings and filtrations, and wherein the washings comprise alternating alcohol and aqueous washings;

b) grinding the MIP compound;

c) comprises drying the MIP compound, and wherein the drying step comprises freeze drying or vacuum drying;

or

d) a combination of the foregoing.